Study record · CJC-1295 (with DAC)
CJC-1295 increases GH and IGF-I in healthy adults
GH increased approximately 2-10-fold for at least 6 days and IGF-I about 1.5-3-fold for 9-11 days; estimated half-life 5.8-8.1 days.
Key result
GH increased approximately 2-10-fold for at least 6 days and IGF-I about 1.5-3-fold for 9-11 days; estimated half-life 5.8-8.1 days.
Study details
Study designTwo randomized placebo-controlled dose-escalation studies
PhasePhase I
PopulationHealthy adults
RouteSubcutaneous
Regimen / exposureSingle ascending doses and repeated weekly/biweekly dosing
DurationUp to several weeks
ComparatorPlacebo
Primary endpoint / questionGH and IGF-I pharmacodynamics
Safety resultEarly pharmacology studies; not designed to establish body-composition or anti-ageing benefit.
Key limitationsHormone target engagement is not evidence of meaningful lifestyle outcomes.
Registry / identifierPMID 16352683